ALNY-ALNYLAM PHARMACEUTICALS INC

Alnylam Pharmaceuticals Maintains 2024 Loss Estimate, Predicts Solid Profit Growth for 2025 Amid Positive Market Sentiment

Member Only Article

Thursday

20 February, 2025

Alnylam Pharmaceuticals is on the brink of a significant turnaround, projecting a shift from a loss to a profit of 41 cents per share in 2025, backed by strong operational performance and a remarkable 74.4% annual share increase. Can this momentum sustain as the biotech landscape evolves?

article image for ALNY

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
0
Key Takeaways
  • Loading...

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.